An Observational Cross-Sectional Survey Exploring the Indications for and Responses to Medical Marijuana Use in Certified Patients in Pennsylvania

Abstract

Introduction/Objectives: Medical cannabis programs across the country vary and differ in their qualifying conditions for medical cannabis use. This has led to a gap in knowledge regarding the specific needs of cannabis patients, including the most common reason patients seek medical cannabis. The purpose of this study was to examine the current needs of medical cannabis patients in order to better inform future research, and to evaluate potential needs in policy changes in states with more restrictive qualifying conditions for medical cannabis use. Methods: A cross-sectional survey study was administered (n = 207) at a Laurel Harvest Labs dispensary in Pennsylvania. Participants were qualified medical cannabis users and were recruited as a convenience sample when entering the dispensary. The survey asked questions regarding participant demographics, medical cannabis qualifying conditions, usage, methods of administration, adverse effects, tolerance, and impact of medical cannabis on medication, alcohol, and tobacco use. Chi-squared or Fisher’s exact tests were conducted for analyses involving categorical data. Results: The mean age of respondents was 36.7 years (SD = 12.8), and the majority were male (61.4%) and white (84.7%). Respondents self-reported that anxiety disorder was the most common qualifying medical condition and the most common comorbid condition (50.1%; 69.3%) for medical cannabis use. Additionally, approximately 95% of users reported having no adverse effects from using medical cannabis, and 90% of users preferred inhalation through vaporization as the preferred method of consumption. More than 50% of participants reported an improvement in their symptoms where only 20% of users reported being tolerant to their current dose. More than 70% of respondents reported that obtaining medical cannabis was “easy” and 54% of users reported that the cost of medical cannabis was not a barrier to access. Conclusions: Anxiety disorder is a prevalent condition for which medical cannabis is used; however, many states do not recognize anxiety disorder as a qualifying condition for medical cannabis. Further research on medical cannabis use for anxiety disorders is needed to evaluate proper dosing and responses to treatment.

Using Smartphone Technology to Track Real-Time Changes in Anxiety/Depression Symptomatology Among Florida Cannabis Users

“…A previous study on Florida medical cannabis users (Rosenthal & Pipitone, 2021) showed that fewer than one-quarter of medical cannabis patients reported needing more cannabis since beginning treatment to get the desired symptomatic effects. Another recent study in Pennsylvania found about 34% of medical cannabis patients reported needing more use over time (Kimless et al, 2022), suggesting that tolerance may not be a primary factor in leading to more cannabis consumption, but may simply be a result of individual differences in how users in the current study consume their cannabis. Last, consumption method, age, and gender did not significantly differ among the different anxiety relief groups.…”

Patients’ perspectives on prescription cannabinoid therapies: a cross-sectional, exploratory, anonymous, one-time web-based survey among German patients

“…In this study, both patients and physicians agreed that cannabis-based medications were particularly beneficial in relieving chronic pain and improving function, with patients rating these effects higher than physicians (42). Interestingly, in a recent survey of 207 patients eligible for the Pennsylvania medical cannabis program (43), anxiety disorders were the most common underlying condition at 50.1%, followed by chronic pain (22.3%) and post-traumatic stress disorder (PTSD) (7.9%). However, approximately 68% of all patients in this study reported using medical cannabis for various pain conditions.…”

Oral CBD-rich hemp extract modulates sterile inflammation in female and male rats

“…Recent surveys of older and younger adults concluded that most CBD users believe there is compelling experimental evidence that CBD-rich hemp products are both safe and effective even though results from rigorously designed studies are equivocal ( Astray et al, 2022 ; Garcia-Romeu et al, 2022 ; Kaufmann et al, 2022 ; Kimless et al, 2022 ; Utter et al, 2022 ; Wysota et al, 2022 ). There remains a need, therefore, for additional clinical trials and preclinical studies that more closely reflect the route of administration and phytochemical composition of CBD products being used.…”